Literature DB >> 15913526

A prospective randomized comparison of the Zadik procedure and chemical ablation in the treatment of ingrown toenails.

Nebal Shaath1, John Shea, Ian Whiteman, Adel Zarugh.   

Abstract

BACKGROUND: We present the results of a prospective randomized trial of the Zadik procedure versus chemical ablation by sodium hydroxide for the treatment of ingrowing toenails.
METHODS: Thirty-eight patients had the Zadik procedure, and 45 patients had chemical ablation by sodium hydroxide. Mean followup was 12.45 months for the Zadik group and 11.69 months for the chemical ablation group.
RESULTS: In the Zadik group, the average return to normal shoe-wear was 2.13 weeks and in the chemical ablation group 3.73 weeks. Average return to normal activity was 2.18 weeks for the Zadik group and 3.89 weeks for the chemical ablation group. The median number of dressings were 3 and 8 for the Zadik and chemical ablation groups, respectively. The pain score, using the visual analogue scale were not statistically significant between the two groups. The recurrence rates were 23 recurrences in the Zadik group (60.5%) and seven recurrences in the chemical ablation group (15.6%).
CONCLUSION: The use of chemical ablation by sodium hydroxide in the treatment of ingrowing toenails shows statistically significant (p < 0.05) reduction in recurrence rates of ingrowing toenails compared to the Zadik procedure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913526     DOI: 10.1177/107110070502600511

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  2 in total

1.  Controversies in the treatment of ingrown nails.

Authors:  Eckart Haneke
Journal:  Dermatol Res Pract       Date:  2012-05-20

2.  Teenage patients with ingrown toenails: treatment with partial matrix excision or segmental phenolization.

Authors:  Murat Korkmaz; Emine Cölgeçen; Yalçın Erdoğan; Ahmet Bal; Kemal Ozyurt
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.